JONES, ROBERT M.,LEHMANN, JUERG,CHEN, WEICHAO,EDWARDS, JEFFREY,MARQUEZ, GLEN,SADEQUE, ABU J.M,KIM, SUN HEE,MORGAN, MICHAEL E.
申请号：
CL2013000785
公开号：
CL2013000785A1
申请日:
2013.03.21
申请国别(地区):
CL
年份:
2013
代理人:
摘要：
The present invention relates to the GPR119 receptor agonists: 3-fluoro-4-(5-fluoro-6-(4-(3-(2-fluoropropan-2-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)pyrimidin-4-ylamino)- N , N- dimethylbenzamide； 3-fluoro-4-(5-fluoro-6-(4-(3-(2-fluoropropan-2-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)pyrimidin-4-ylamino)- N -methylbenzamide； and 3-fluoro-4-(5-fluoro-6-(4-(3-(2-fluoropropan-2-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)pyrimidin-4-ylamino)benzamide, and pharmaceutically acceptable salts, solvates, and hydrates thereof, that are useful as a single pharmaceutical agent or in combination with one or more additional pharmaceutical agents, such as, a DPP-IV inhibitor, a biguanide, an alpha-glucosidase inhibitor, an insulin analogue, a sulfonylurea, an SGLT2 inhibitor, a meglitinide, a thiazolidinedione, or an anti-diabetic peptide analogue, in the treatment of, for example, a disorder selected from: a GPR119-receptor-related disorder； a condition ameliorated by increasing secretion of an incretin； a condition ameliorated by increasing a blood incretin level； a condition characterized by low bone mass； a neurological disorder； a metabolic-related disorder； type 2 diabetes； obesity； and complications related thereto.COMPUESTOS 3-FLUORO-4-(5-FLUORO-6-(4-(3-(2-FLUOROPROPAN-2-IL)-1,2,4-OXADIAZOL-5-IL)PIPERIDIN-1-IL)PIRIMIDIN-4-ILAMINO)(-N,N-DIMETILBENZAMIDA O –N-METILBENZAMIDA O –BENZAMIDA)； COMPOSICION FARMACEUTICA； METODO DE PREPARACION； PRODUCTO FARMACEUTICO； METODO DE TRATAMIENTO； USO PARA TRATAR UN TRASTORNO NEUROLOGICO, ENTRE OTROS.
